The system devices advisory panel also recommended the development of additional safety data as a basis for expanding the indicated use to include adult patients.
Dr Eli Pines, vice president of research, said: “We are pleased with the panel’s recommendation to approve Repel-CV and we look forward to discussions with the FDA on securing approval to market Repel-CV for the initial indication. We will also immediately seek FDA approval to initiate the adult clinical study.”